Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Q3 2022 Earnings Conference Call November 1, 2022 8:00 AM ET
Company Participants
Todd Tushla - VP of IR
Kevin Gorman - CEO
Matt Abernethy - CFO
Eric Benevich - Chief Commercial Officer
Eiry Roberts - Chief Medical Officer
Kyle Gano - Chief Business Development & Strategy Officer
Conference Call Participants
Tazeen Ahmad - Bank of America
Paul Matteis - Stifel
Phil Nadeau - Cowen & Company
Neena Bitritto-Garg - Citi
Anupam Rama - JPMorgan
Brian Abrahams - RBC Capital Markets
Carter Gould - Barclays
Chris Shibutani - Goldman Sachs
Myles Minter - William Blair
Brian Skorney - Baird
Laura Chico - Wedbush
Ashish Sharma - UBS
Jeff Hung - Morgan Stanley
Jay Olson - Oppenheimer
Marc Goodman - SVB
David Amsellem - Piper Sandler
Uy Ear - Mizuho Securities
Conor MacKay - BMO Capital Markets
Yatin Suneja - Guggenheim Partners
Mohit Bansal - Wells Fargo
Sumant Kulkarni - Canaccord Genuity
Operator
Good day, everyone. And welcome to today's Neurocrine Biosciences Reports Third Quarter Results. At this time, all participants are in a listen-only mode. Later, you will have the opportunity to ask questions, during the question-and-answer session. [Operator Instructions] Please note that this call may be recorded, and I will be standing by should you need any assistance.
It is now my pleasure to turn the conference over to Todd Tushla, Vice President of Investor Relations. Please go ahead.
Todd Tushla
Thank you, operator. Good afternoon, everyone. Welcome to our third quarter 2022 earnings call. On today’s call, we have Kevin Gorman, our Chief Executive Officer; Matt Abernethy, our Chief Financial Officer; Eiry Roberts, our Chief Medical Officer; Eric Benevich, our Chief Commercial Officer; and Kyle Gano, our Chief Business Development and Strategy Officer.
During our call, we will be making forward-looking statements. These statements are subject to certain risks and uncertainties, and our actual results may differ materially. I encourage you to review the risk factors discussed in our latest SEC filings. We will go to Q&A after prepared remarks and we will do our best to get everyone’s questions.
With that, I'll hand the call to Kevin.
Kevin Gorman
Thanks, Todd, and good morning, everyone. Well, another very nice quarter of INGREZZA sales and this sets us up well for continued growth in Q4. I'm pleased to see that the investments that we have been making in INGREZZA this year and last year are starting to show results and it is our expectation we will continue to increase our ability to treat TD patients so they don't suffer needlessly.